AHA names 2017’s top advances in heart disease and stroke research
Summary: Glucose-lowering SGLT2 inhibitors, the inflammation-lowering drug Canakinumab, cholesterol-lowering PCSK9 inhibitors, and using gene editing to fix mutations, were named by the AHA in its list of the top advances in heart disease and stroke research of 2017. [This article first appeared on the website LongevityFacts. Author: Brady Hartman.] Here’s an executive summary of four of these top research advances: Fixing Genetic Mutation in Human Embryos When… Continue reading "AHA names 2017’s top advances in heart disease and stroke research"
